CTOs on the Move

ParaPRO

www.parapro.com

 
ParaPRO is a Carmel, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.parapro.com
  • 11550 N Meridian St Ste 600
    Carmel, IN USA 46032
  • Phone: 317.428.4597

Executives

Name Title Contact Details

Similar Companies

Care Services

Care Services is a Eastlake, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AuroSource

AuroSource is a Cranbury, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NeuBase Therapeutics

NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes

Virbac

At Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving animals` quality of life and to shaping together the future of animal health.

Oncology Pharma

Oncology Pharma, Inc. is a pioneering oncology company dedicated to licensing, developing, manufacturing and commercializing therapeutics. The company has assembled a team of executives and advisors with proven multi-disciplinary expertise in the field of oncology, therapeutics and leadership to identify, negotiate and amalgamate “best in class” research, technologies, therapeutics and delivery mechanisms that are synergistic and collaborative. The goal is to create value, reduce costs and increase the speed of regulatory approval and commercialization of effective and safer cancer drugs.